This is a Moderna news story, published by Yahoo Finance, that relates primarily to Moderna news.
For more Moderna news, you can click here:
more Moderna newsFor more Moderna news, you can click here:
more Moderna newsFor more vaccine development news, you can click here:
more vaccine development newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
vaccine sales. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest former vaccine news, Moderna executives news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
European vaccine marketInsider
•81% Informative
Sales of its COVID-19 vaccine dropped 37% year-over-year in the second quarter .
Moderna lowered its annual sales forecast for the year to between $3 billion and $3.5 billion .
Shares of Moderna fell as much as 21% on Thursday as a result.
VR Score
86
Informative language
89
Neutral language
53
Article tone
semi-formal
Language
English
Language complexity
48
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links